Not yet recruitingPhase 2NCT07445815

A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody

Studying Rabies

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lanzhou Institute of Biological Products Co., Ltd
Principal Investigator
Chaolin Huang
Wuhan Jinyintan Hospital
Intervention
Recombinant Human Rabies Virus Monoclonal Antibody Injection(drug)
Enrollment
200 target
Eligibility
18-60 years · All sexes
Timeline
20262026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07445815 on ClinicalTrials.gov

Other trials for Rabies

Additional recruiting or active studies for the same condition.

See all trials for Rabies

← Back to all trials